Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 43 results
Filters: First Letter Of Title is H  [Clear All Filters]
Found 43 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

H

Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Mitsuya Y, Winters MA, W Fessel J, et al. "HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL." J. Acquir. Immune Defic. Syndr.. 2006;43(1):56-9.
Rhee S-Y, Kantor R, Katzenstein DA, et al. "HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes." AIDS. 2006;20(5):643-51.
Porter KA, Cole SR, Eron JJ, et al. "HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study." Antimicrob. Agents Chemother.. 2012;56(2):995-1000.
Kantor R, Bettendorf D, Bosch RJ, et al. "HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077." PLoS ONE. 2014;9(4):e93537.
Imamichi H, Degray G, Asmuth DM, et al. "HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy." AIDS. 2011;25(2):159-64.
Hubbard JJ, Greenwell-Wild T, Barrett L, et al. "Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a." J. Infect. Dis.. 2012;205(9):1443-7.
Lee SA, Mefford JA, Huang Y, et al. "Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans." AIDS. 2016;30(11):1807-15.
Funderburg N, Lederman MM, Feng Z, et al. "Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2." Proc. Natl. Acad. Sci. U.S.A.. 2007;104(47):18631-5.
Haas DW. "Human genetic variability and HIV treatment response." Curr HIV/AIDS Rep. 2006;3(2):53-8.
Vardhanabhuti S, Katzenstein D, Bartlett J, Kumarasamy N, Wallis CL. "Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230." Open Forum Infect Dis. 2016;3(3):ofw154.
Shiboski CH, Lee A, Chen H, et al. "Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy." AIDS. 2016;30(10):1573-82.
Matoga MM, Hosseinipour MC, Aga E, et al. "Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings." Antivir. Ther. (Lond.). 2016.

Pages